Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 473 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Paranasal Sinus Diseases Clear all
Completed Not applicable Interventional Results available

Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children

NCT00465530
View directory record Official record
Conditions
Sinusitis
Interventions
Saline, Gentamycin
Drug
Lead sponsor
Julie Wei, MD
Other
Eligibility
4 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Shawnee, Kansas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional

Hemostatic Matrix in Endoscopic Sinus Surgery

NCT00242437
View directory record Official record
Conditions
Sinusitis
Interventions
Hemostatic matrix, bovine thrombin
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2005 – 2006
U.S. locations
3
States / cities
Summit, New Jersey • Charleston, South Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Not applicable Interventional

Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum

NCT00896883
View directory record Official record
Conditions
Sinusitis
Interventions
Middle Turbinate Implant
Device
Lead sponsor
ENTrigue Surgical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Sewell, New Jersey • Boerne, Texas • College Station, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Exploration of Pupil Dilation in Horner's Patients Taking Flomax

NCT03615508
View directory record Official record
Conditions
Horner Syndrome
Interventions
10% phenylephrine
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Not applicable Interventional Results available

Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps

NCT02927834
View directory record Official record
Conditions
Sinusitis
Interventions
6 day Prednisone, Augmentin, 21 day Prednisone
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 1, 2026, 9:29 PM EDT
Withdrawn Phase 2 Interventional

Preventing Frequent Sinus Infections in HIV-Infected Patients

NCT00000752
View directory record Official record
Conditions
HIV Infections, Sinusitis
Interventions
Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

NCT01044433
View directory record Official record
Conditions
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
lapatinib ditosylate, capecitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Not applicable Interventional Results available

Left Bundle Area Versus Selective His Bundle Pacing

NCT04093414
View directory record Official record
Conditions
Bradycardia, Sinus Node Dysfunction, Atrioventricular Block
Interventions
Select Secure pacing lead
Device
Lead sponsor
David Haines, MD
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 4 Interventional Results available

Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery

NCT03757715
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine, Dexamethasone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

NCT07148050
View directory record Official record
Conditions
Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Liposarcoma, Rhabdomyosarcoma, Embryonal Sarcoma of Liver, Wilms Tumor, Hepatocellular Carcinoma, Hepatoblastoma
Interventions
SC-CAR.GPC3xIL15.21 CAR T cells
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Not applicable Interventional

Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)

NCT05298709
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Hyperventilation and CO2 challenge
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Not applicable Interventional Results available

Xylitol Versus Saline in Chronic Sinusitis

NCT00924404
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Xylitol, Saline
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages

NCT03274414
View directory record Official record
Conditions
Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
Interventions
Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection, cisplatin and etoposide
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

NCT00970502
View directory record Official record
Conditions
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms, Cancer of the Head
Interventions
erlotinib + celecoxib
Drug
Lead sponsor
Johnny Kao
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
REC-994, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated No phase listed Observational

Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00898742
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Completed No phase listed Observational

DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

NCT01434355
View directory record Official record
Conditions
Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 19 Years
Enrollment
932 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 1, 2026, 9:29 PM EDT
Not listed Phase 2 Interventional

Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer

NCT00022217
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
carboplatin, cisplatin-e therapeutic implant, paclitaxel
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Phoenix, Arizona • Tucson, Arizona • Evanston, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Completed No phase listed Observational

Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting

NCT00355160
View directory record Official record
Conditions
Headache, Sinusitis, Rhinitis, Facial Pain
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 1, 2026, 9:29 PM EDT
Terminated Phase 3 Interventional

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

NCT05039359
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
FlecIH-103
Drug
Lead sponsor
InCarda Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 1, 2026, 9:29 PM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00513435
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 1, 2026, 9:29 PM EDT
Not yet recruiting Phase 1 Interventional

Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

NCT07224568
View directory record Official record
Conditions
Solid Tumor (Excluding CNS), Hepatocellular Carcinoma, Liver Cell Carcinoma, Liposarcoma, Yolk Sac Tumor, Rhabdomyosarcoma
Interventions
SC-CAR.GPC3xIL15.21 CAR T cells
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 1, 2026, 9:29 PM EDT